

FRANK H. MORRIS, M.D., F.A.C.C.

CURRICULUM VITAE

OFFICE ADDRESSES: Lutherville Personal Physicians
1734 York Road
Lutherville, MD 21093
(P) 443-275-5000
Research Fax: 1-410-741-3348

Overlea Personal Physicians
7602 Belair Road
Baltimore, MD 21236
(P) 410-663-6986
(F) 410-663-6985
Research Fax: 1-410-741-3348

EDUCATION: Loyola College
Baltimore, Maryland
Graduated Cum Laude, B.A Biology
June 1971

University of Maryland School of Medicine
Baltimore, Maryland
M.D.
June 1975

POSTDOCTORAL TRAINING

Internship Straight Medicine Internship
University of Maryland Hospital
Baltimore, Maryland
07/1/75 – 06/30/76

Residencies Junior Assistant Resident in Medicine
University of Maryland Hospital
Baltimore, Maryland
07/1/76 – 06/30/77

Assistant Resident in Medicine
University of Maryland Hospital
07/1/77 – 06/30/78

Fellowship
Fellow in Medicine in Cardiology
Veterans Administration Hospital
Loch Raven Blvd
Baltimore, Maryland
07/01/78 – 06/30/80

WORK HISTORY:

April 2011 – Present
Lutherville Personal Physicians
1734 York Road
Lutherville, Maryland

Overlea Personal Physicians
7602 Belair Road
Baltimore, MD

1996 – March 2011
Midatlantic Cardiovascular Associates
Towson, Maryland

1980 – 1996
Private Cardiology Practice
Baltimore, Maryland

**MEDICAL STAFF
APPOINTMENTS**

Mercy Medical Center
St. Joseph Medical Center
Union Memorial Hospital
Greater Baltimore Medical Center

**LICENSURE AND
CERTIFICATIONS**

Passed FLEX, June 1975
State of Maryland

American Board of Internal Medicine
Board Certified – September 1978

American College of Cardiology
Board Certified – November 1981

Fellow American College of Cardiology
June 1981

American Board of Internal Medicine
Interventional Cardiology
1999 – 2009

Advanced Cardiac Life Support
March 2003

AWARDS:

1970	Gold Medal in Theology – Loyola College
1971	Gold Medal in Biology – Loyola College
1974	Honors in Pediatrics, Obstetrics and Gynecology, Surgery; University of Maryland School of Medicine
1983	Outstanding Young Men of America

SOCIETY

MEMBERSHIPS:

- Baltimore City Medical Society
- Baltimore County Medical
- American Heart Association
- American College of Cardiology
- Alpha Sigma Nu Jesuit Honor Society

PUBLICATIONS:

1. Schuster, E.H., Conrad, E., **Morris, F.H.**, et al: Systemic sarcoidosis and electrocardiographic conduction abnormalities: Electrophysiologic evaluation of two patients. CHEST 78L pp 601-604, October 1980.
2. Dutta, S.K., Plotnick, G.D., Williams, R., **Morris, F.H.**: Massive dilation of the inferior vena cava: Association with tricuspid regurgitation. JAMA 239: pp.135-136, January 9, 1978.
3. Fisher, M.L., Kelemen, M.H., Collins, M.D., Holder, L., Winzelberg, G., Plotnick, G.D., **Morris, F.H.**, et al: Technetium-99M-pyrophosphate scintigraphy in patients with suspected acute myocardial infarction: impact of interobserver variability. AMERICAN Heart Journal 100:pp.347-352, 1985.
4. Fisher, M.L., Kelemen, M.H., Collins, M.D., **Morris F.H.**, et al: Routine serum enzyme tests in the diagnosis of acute myocardial infarction. Cost effectiveness. ARCHIVES OF INTERNAL MEDICINE 143:pp.1541-1543, 1983.
5. Fisher, M.L., Carliner, N.H., Becker, L.C., Peters, R.W., Plotnick, G.D., **Morris, F.H.**: Serum enzyme test in the diagnosis of acute myocardial infarction: Optimal frequency sampling. JAMA 249:pp.393-394, 1983.

ABSTRACTS:

1. Wang J.C., Coombs V.J., Loughrey M.B., Lowry D.R., Meilman H., Cummings C.C., Prewitt K.C., Drossner M.N., **Morris F.**, Plack R., Topper D., Gottlieb S.O., Midei M.G. In-Hospital and 6-Month Clinical Outcomes of Left Main Coronary Artery (LMCA) Percutaneous Coronary Intervention (PCI) in a Community Hospital Setting. Transcatheter Cardiovascular Therapeutics. Washington, DC 2005
2. Prewitt K., Coombs V, Wang J, Drossner M, Plack R, Lowry D, Loughrey M, Meilman H, **Morris F**, Cummings C, Brooks S, Midei M. Clinical Outcomes in the Utilization of Drug Eluting Stents in Patients with Long Coronary Lesions. The Society for Cardiovascular Angiography and Interventions. 29th Annual Scientific Sessions 2005.

CLINICAL TRIAL EXPERIENCE:

1. **Lunar**: A 12-week Randomized, Open-label 3-arm, Parallel Group, Multicenter Phase IIIb Study Comparing Efficacy and Safety of Rosuvastatin 20mg and 40mg With That of Atorvastatin 80 mg in Subjects With Acute Coronary Syndromes. AstraZeneca 2003 – 2007
2. **SIMPADICO**: Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of the Celacade™ System in Improving Walking Distance in Patients With Intermittent Claudication Secondary to Peripheral Arterial Disease. Vasogen 2003 – 2005
3. **ARISE**: Aggressive Reduction of Inflammation Stops Events. Atherogenics 2003
4. **EVEREST**: Protocol 156-03-236: Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Long Term Efficacy and Safety of Oral Tolvaptan Tablets in Subjects Hospitalized With Worsening Congestive Heart Failure. Otsuka Pharmaceutical 2003
5. **JUPITER**: A Randomized, Double-Blind, Placebo Controlled, Multicenter, Phase 3 Study of Rosuvastatin (CRESTOR®) 20 mg in the Prevention of Cardiovascular Events Among Subjects With Low Levels of LDL Cholesterol & Elevated Levels of C-Reactive Protein. AstraZeneca 2003 – 2008
6. **ILLUMINATE**: Phase 3 Multi Center, Double Blind, Randomized, Parallel Group Evaluation Of The Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily (Qd), Compared With Atorvastatin Alone, On The Occurrence Of Major Cardiovascular Events In Subjects With Coronary Heart Disease Or Risk Equivalents. Pfizer 2004 – 2007

7. **RELY:** Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation: Prospective, Multi-centre, Parallel-group, Non-inferiority Trial. Boehringer Ingelheim Pharmaceuticals 2005 – 2009
8. **SPIRIT III:** A Clinical Evaluation of the Investigational Device XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) in the Treatment of Subjects with de Novo Native Coronary Artery Lesions. Abbott Vascular 2005 – Present
9. **ZOMAXX:** A Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the ZoMaxx Drug Eluting Coronary Stent System as Compared to the TAXUS™ Express2™ Paclitaxel-Eluting Stent in de Novo Coronary Artery Lesions. Abbott Vascular 2005 – Present
10. **SPIRIT IV** Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Subjects with de Novo Native Coronary Artery Lesions. Abbott Vascular 2006 – Present
11. **PRECISION:** A Randomized, Double Blind, Parallel-Group Study of Cardiovascular Safety In Osteoarthritis or Rheumatoid Arthritis Patients With or at High Risk for Cardiovascular Disease Comparing Celecoxib With Naproxen and Ibuprofen. Pfizer 2006 – Present
12. **TRA-2P-TIMI-50:** A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With a History of Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events. Schering Plough 2007 – Present
13. **ACCOMPLISH:** A Prospective, Multinational, Multicenter Trial to Compare the Effects of Amlodipine/Benazepril to Benazepril and Hydrochlorothiazide Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients With High Risk Hypertension. Novartis 2007 – 2008
14. **RELY-ABLE:** Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed the RE-LY Trial and a Cluster Randomised Trial to Assess the Effect of a Knowledge Translation Intervention on Patient Outcomes. Boehringer Ingelheim Pharmaceutical 2008 – Present
15. **PROTOCOL # NC20971** A Randomized, Double-blind, Placebo-controlled Study Assessing the Effect of RO4607381 on Cardiovascular Mortality and Morbidity in Clinically Stable Patients With a Recent Acute Coronary Syndrome. Hoffman La-Roche 2008 – Present

16. **ENGAGE TIMI 48:** A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Multi-Center, Multi-National Study for Evaluation of Efficacy and Safety of DU-176b Versus Warfarin In Subjects With Atrial Fibrillation - Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation. Daiichi Sankyo Inc. 2008 – Present

17. **XIENCE V:** XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study (XIENCE V® USA Long Term Follow-up Cohort). Abbott Vascular 2008 – Present

Revised March 2011